Interleukin-15/Interleukin-15Rα Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8+ T Cells
Open Access
- 15 April 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (8), 2972-2983
- https://doi.org/10.1158/0008-5472.can-08-0045
Abstract
Tumors often escape immune-mediated destruction by suppressing lymphocyte infiltration or effector function. New approaches are needed that overcome this suppression and thereby augment the tumoricidal capacity of tumor-reactive lymphocytes. The cytokine interleukin-15 (IL-15) promotes proliferation and effector capacity of CD8+ T cells, natural killer (NK) cells, and NKT cells; however, it has a short half-life and high doses are needed to achieve functional responses in vivo. The biological activity of IL-15 can be dramatically increased by complexing this cytokine to its soluble receptor, IL-15Rα. Here, we report that in vivo delivery of IL-15/IL-15Rα complexes triggers rapid and significant regression of established solid tumors in two murine models. Despite a marked expansion of IL-2/IL-15Rβ+ cells in lymphoid organs and peripheral blood following treatment with IL-15/IL-15Rα complexes, the destruction of solid tumors was orchestrated by tumor-resident rather than newly infiltrating CD8+ T cells. Our data provide novel insights into the use of IL-15/IL-15Rα complexes to relieve tumor-resident T cells from functional suppression by the tumor microenvironment and have significant implications for cancer immunotherapy and treatment of chronic infections. [Cancer Res 2008;68(8):2972–83]Keywords
Other Versions
This publication has 48 references indexed in Scilit:
- Principles of adoptive T cell cancer therapyJCI Insight, 2007
- DC-based cancer vaccinesJCI Insight, 2007
- In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumorThe Journal of Experimental Medicine, 2007
- Cancer Immunotherapy Is More Than a Numbers GameScience, 2006
- The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine designNature Reviews Immunology, 2006
- Converting IL-15 to a superagonist by binding to soluble IL-15RαProceedings of the National Academy of Sciences of the United States of America, 2006
- Adoptive immunotherapy for cancer: building on successNature Reviews Immunology, 2006
- Cytokines in cancer immunity and immunotherapyImmunological Reviews, 2004
- Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T CellsThe Journal of Experimental Medicine, 2004
- Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in MiceScience, 1999